Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Vertex Pharmaceuticals

Stock Market: Three Top Names In Buy Zones, One With Earnings Due

The stock market awaits reports from Home Depot, Disney and Cisco Systems. Cisco, Costco and Vertex are in buy zones.

Investors Business Daily

Stocks With Rising Relative Strength: Vertex Pharmaceuticals

Stocks With Rising Relative Strength: Vertex Pharmaceuticals

Vertex Pharmaceuticals shows rising price performance, earning an upgrade to its IBD Relative Strength Rating

Investors Business Daily

Vertex Pharmaceuticals Earns RS Rating Upgrade

Vertex Pharmaceuticals Earns RS Rating Upgrade

A Relative Strength Rating upgrade for Vertex Pharmaceuticals shows improving technical performance. Will it continue?

Investors Business Daily

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Is Vertex Pharmaceuticals Stock Outperforming the Nasdaq?

Vertex Pharmaceuticals has outperformed the Nasdaq over the past year, and analysts remain moderately bullish about the stock's prospects.

Are Wall Street Analysts Bullish on Vertex Pharmaceuticals Stock?

Vertex Pharmaceuticals has outperformed the broader market in 2024 but Wall Street analysts remain cautiously bullish about the stock's potential.

Microsoft, Nvidia Shunned. Meet The New Big 'Daddy' On Wall Street.

The best mutual funds spurned Nvidia and Microsoft last month. They got up and went to GoDaddy and these builders.

Investors Business Daily

Vertex Stock Hit All-Time High, Paused, Rising Again

A Relative Strength Rating upgrade for Vertex stock shows improving technical performance. Will it continue?

Investors Business Daily

inkl

Read news from The Economist, FT, and more,
with one subscription

Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?

Vertex Pharmaceuticals (VRTX) Earnings Review: Is it Time to Buy?

After a solid first-quarter earnings report, Vertex Pharmaceuticals (VRTX) comfortably topped analysts’ earnings and revenue estimates in the first quarter. But should investors consider adding the stock to their portfolio now? Let’s look at its financial metrics to gauge its prospects….

Vertex's Pain Drug Could Be Worth Up To $11.4 Billion — Ongoing Debate Sparks Shares

Vertex's Pain Drug Could Be Worth Up To $11.4 Billion — Ongoing Debate Sparks Shares

Vertex stock advanced Tuesday as analysts debated the company's pain drug with one saying it could eventually generate $11.4 billion in sales.

Investors Business Daily

Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised

Dow Jones Lower Despite PPI Inflation Relief; Nvidia, Microsoft Price Targets Raised

The Dow fell after initially rising on the PPI inflation report on the stock market today. Analysts hiked Microsoft and Nvidia price targets.

Investors Business Daily

Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It

Alpine Catapults 37% After Vertex Pledges $4.9 Billion To Buy It

Vertex Pharmaceuticals will pay $4.9 billion to acquire Alpine Immune Sciences. Alpine stock rocketed almost 21% on rumors of the deal.

Investors Business Daily

Three S&P 500 Giants Lead This List Of Stocks Near Buy Points

Three S&P 500 Giants Lead This List Of Stocks Near Buy Points

S&P 500 stocks Lennar, Vertex Pharmaceuticals and Royal Caribbean lead this list of five stocks trading around buy points.

Investors Business Daily

Here's Why IBD Stock Of The Day Vertex Pharmaceuticals Is Newly Actionable

Here's Why IBD Stock Of The Day Vertex Pharmaceuticals Is Newly Actionable

Vertex is the IBD Stock Of The Day. VRTX stock bounced off its 50-day line as investors watch for the first sales of its gene-editing drug.

Investors Business Daily

This Could Be the Next Blockbuster Drug Stock to Buy

This Could Be the Next Blockbuster Drug Stock to Buy

Vertex Pharmaceuticals just released data from its experimental drug to relieve pain, with no risk of addiction and very few side effects. This opioid alternative could give Vertex - already a powerhouse in the cystic fibrosis segment - another blockbuster drug to add to its portfolio.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Stock Market Rally Surges To 2023 Highs As Fed Pivots Toward Rate Cuts: Weekly Review

The Dow Jones hit a record high while the S&P 500, Nasdaq and Russell 2000 set 2023 highs as the Fed signaled multiple rate cuts next year.

Stocks Surge on FOMC Meeting Results

What you need to know… The S&P 500 Index ($SPX ) (SPY ) is up +1.16%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is up +1.05%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +1.2%. Stocks are surging this afternoon, with the S&P 500 and...

Stocks Slightly Higher Going into FOMC Meeting Results

What you need to know… The S&P 500 Index ($SPX ) (SPY ) today is up +0.13%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -0.06%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is up +0.30%. Stocks this morning are mixed, with the S&P 500...

Investors Business Daily

Vertex Stock Breaks Out On Phase 2 Results For Opioid Alternative

Vertex stock rallied 13% Wednesday after reporting "statistically significant" results in a Phase 2 study for a pain drug.

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

Here's What The FDA Approval Of Gene Editing For Sickle Cell Means For CRSP Stock And The Future Of Medicine

Biotech stocks could be at a major turning point after FDA approval of the first gene editing drug using Crispr technology. But gene editing therapies aren’t without risk, and questions remain about the safety and cost effectiveness of these experimental treatments.

US approves two gene therapies for sickle cell disease

The U.S. Food and Drug Administration on Friday approved a pair of gene therapies for sickle cell disease, including the first treatment based on the breakthrough CRISPR gene editing technology.

The First CRISPR Gene Therapy Was Finally Approved In The US — Here’s How It Works

Using the gene editing tool CRISPR, the new therapy promises a cure for those with sickle cell anemia and beta thalassemia, but cost could be a barrier to care.

Vertex Pharmaceuticals (VRTX) Post-Earnings Analysis: Is It Time to Buy the Stock?

After a solid third-quarter earnings report, does Vertex Pharmaceuticals (VRTX) deserve a place in your portfolio? Let’s look at its financial metrics to gauge its prospects….

Investors Business Daily

Meta Stock Leads 5 Names Showing Resilience In Market Downturn

Meta leads five resilient stocks worth watching. But investors need to be patient amid the market correction.

Investors Business Daily

Vertex Pharmaceuticals Stock Shows Rising Relative Strength, Hits 80+

Vertex Pharmaceuticals shows improving price performance, earning an upgrade to its IBD Relative Strength Rating from 78 to 81.

Investors Business Daily

Vertex Stock Surges As Investors Eye Its Chockfull Calendar Of Expected Drug News

Vertex Pharmaceuticals faces numerous catalysts this year and next, an analyst said Wednesday. And VRTX stock popped.

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

US Federal Reserve

Intel Corporation

the Justice Department

the Federal Reserve

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Sickle Cell Disease

Places

291,133 stories

118,006 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play